Search This Blog

Tuesday, June 11, 2019

ContraVir up on positive CRV431 data in hepatitis B

Thinly traded nano cap ContraVir Pharmaceuticals (CTRV +21.4%) is up average volume in early trade in apparent response to just-published research on cyclophilin inhibitor CRV431 in a mouse model of hepatitis B (HBV).
The data, appearing in PLOS ONE, showed that CRV431 significantly reduced HBV DNA in the liver of transgenic mice in a dose-dependent manner while also reducing serum levels of surface antigen (HBsAg) (surface antigen signifies an active infection).
CRV431 is currently in Phase 1 development.

Kroger To Introduce CBD Products In 17 States

Kroger Co KR 0.04% is the latest company to introduce CBD products to its U.S. store shelves.
The grocery chain’s corporate affairs manager for its Michigan division, Rachel Hurst, said the company will begin the rollout this week in 17 states, according to The Detroit News.

Why It Matters

Kroger’s decision to sell CBD lotions, oils and other products makes it the latest major American chain to get involved with the products.
Others to recently enter the market include convenience store chain Sheetz, which announced in May 2019 that it would begin selling CBD at over 140 locations in the U.S. Others new CBD retailers include Walgreens Boots Alliance Inc WBA and CVS Health Corp CVS.
Retail giants like Walmart Inc WMT and Target Corporation TGT have also reportedly explored the possibility of CBD sales in recent months.
Small, struggling industries may benefit from CBD sales as well: one video rental store in Michigan reported a sales boost after it began offering CBD products.

What’s Next

The Food and Drug Administration held a hearing in May 2019 to hear from the CBD industry about the cannabinoid and its possible inclusion in edibles. No determination has been made at this time.

Barclays starts Evolus at Underweight

Analyst Balaji Prasad initiates coverage

Barclays starts Foamix at Overweight

Analyst Balaji Prasad initiates coverage

Barclays starts Jazz Pharma at Overweight

Analyst Balaji Prasad initiates coverage

Barclays starts Revance at Overweight

Analyst Balaji Prasad initiates coverage